Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2015

Study Completion Date

June 30, 2020

Conditions
Prostate Cancer
Interventions
DRUG

117Lu-J591

There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.

Trial Locations (1)

10021

Weill Cornell Medical College-New York Presbyterian Hospital, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT00538668 - Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody | Biotech Hunter | Biotech Hunter